Apollomics CFO Lin Peter Kuan-How Sells 10,000 Shares
The Chief Financial Officer of Apollomics, Inc. sold significant shares on June 15, 2026.
Key Points
- Lin Peter Kuan-How, CFO of Apollomics, Inc., sold 10,000 shares on June 15, 2026.
- Apollomics, Inc. trades on NasdaqCM under APLM with a market cap of about $31.8 million.
- Recent analyst ratings include a reiterated 'buy' from H.C. Wainwright with a $17 target.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 15, 2026, Lin Peter Kuan-How, the Chief Financial Officer of Apollomics, Inc. (NasdaqCM: APLM), sold 10,000 shares of the company. This insider transaction did not involve any planned sale program and occurred at a time when the stock was trading near $14.49.
Insider Buying and Selling at Apollomics, Inc.
Lin Peter Kuan-How was active on June 15, selling 10,000 shares without a planned sale program. Additionally, he sold 3,588 shares at an average price of $13.85. On the same day, he also bought 10,000 shares. Other notable insider transactions include Chen Hung-Wen, the CEO, purchasing 5,000 shares, and Chen Hong-Jung buying 500 shares.
Apollomics, Inc. Stock Down 47.3%
Shares of Apollomics, Inc. (NasdaqCM: APLM) traded near $14.49 recently. The company has a market cap of approximately $31.8 million and a forward P/E ratio of -22.29, indicating it isn't profitable. The stock has a 52-week low of $3.66 and a high of $42.12, with a 50-day moving average of $14.25 and a 200-day moving average of $16.91. The company shows a current ratio of 0.96 and a quick ratio of 0.91, reflecting its liquidity position.
Analysts Set New Price Targets
Analysts at H.C. Wainwright reiterated their 'buy' rating for Apollomics, Inc. with a price target of $17 on November 20, 2023. EF Hutton maintained a 'buy' rating with a target of $25 on May 25, 2023. These ratings suggest confidence in the company's future performance despite its current financial challenges.
About Apollomics, Inc.
Apollomics, Inc. is a clinical-stage biopharmaceutical company based in Foster City, California. Founded in 2015, it focuses on developing cancer therapies that harness the immune system and target molecular pathways. The company is working on several products, including Vebreltinib for non-small cell lung cancer and APL-102 for cancer treatment. Apollomics employs 14 people and is led by CEO Mr. Hung-Wen Chen.
Bottom Line
The insider selling by Apollomics' CFO comes as the company continues to develop its oncology therapies. Investors often watch insider transactions for potential signals about the company's prospects. However, it's important to remember that Form 13F filings and insider transactions reflect past actions and may not indicate current positions or intentions.
Get Apollomics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $APLM, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.